Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients: Insights From the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study
The purpose of this study was to determine the factors associated with the favorable effect of pioglitazone on atheroma progression. Diabetes mellitus is associated with accelerated coronary atheroma progression. Pioglitazone slowed progression compared with glimepiride in this population. In all, 3...
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology 2011-01, Vol.57 (2), p.153-159 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 159 |
|---|---|
| container_issue | 2 |
| container_start_page | 153 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 57 |
| creator | NICHOLLS, Stephen J MURAT TUZCU, E WOLSKI, Kathy BAYTURAN, Ozgur LAVOIE, Andrea UNO, Kiyoko KUPFER, Stuart PEREZ, Alfonso NESTO, Richard NISSEN, Steven E |
| description | The purpose of this study was to determine the factors associated with the favorable effect of pioglitazone on atheroma progression.
Diabetes mellitus is associated with accelerated coronary atheroma progression. Pioglitazone slowed progression compared with glimepiride in this population.
In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. Coronary atheroma progression was evaluated by serial intravascular ultrasound. The relationship between changes in biochemical parameters, percent atheroma volume, and total atheroma volume was investigated.
Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol (HDL-C) and reductions in glycated hemoglobin, triglycerides, and C-reactive protein. Significant correlations were observed between changes in percent atheroma volume and triglycerides (r = 0.15, p = 0.04), triglyceride/HDL-C ratio (r = 0.16, p = 0.03), and glycated hemoglobin (r = 0.16, p = 0.03) with pioglitazone, and changes in low-density lipoprotein cholesterol (r = -0.15, p = 0.05), apolipoprotein B (r = -0.16, p = 0.04), and apolipoprotein A-I (r = -0.20, p = 0.01) with glimepiride. Substantial atheroma regression, compared to progression, was associated with greater relative increases in HDL-C (14.2% vs. 7.8%, p = 0.04), relative decreases in triglycerides (-13.3% vs. -1.9%, p = 0.045), triglyceride/HDL-C ratio (-22.5 vs. -9.9%, p = 0.05), and decrease in glycated hemoglobin (-0.6% vs. -0.3%, p = 0.01). Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were associated with changes in percent atheroma volume (p = 0.03) and total atheroma volume (p = 0.02).
Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed atheroma progression in diabetic patients. This finding highlights the potential importance of targeting atherogenic dyslipidemia in diabetic patients with coronary artery disease. |
| doi_str_mv | 10.1016/j.jacc.2010.06.055 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_822902156</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>822902156</sourcerecordid><originalsourceid>FETCH-LOGICAL-p301t-f8fe4ad9f70869d492a40b7120c4be3a6016bd0ee633b5c88fc3b09e8c4440833</originalsourceid><addsrcrecordid>eNp9kkuP0zAUhQMCMWXgD7BAlkaIYZGOnafDrnQ6TKSiVu0glpXj3CSuXDvYTlH59bgz5blg41g3n845vvcGwSuCxwST7Go73jLOxxH2BZyNcZo-DkYkTWkYp0X-JBjhPE5Dgov8LHhu7RZjnFFSPAvOIhIRktFs9OjTXH8DI1SLXAfozohWHrgv1HB1K9ouvAZlhTugueh1b7QDodC00xKsA6MlWjEnNCotmliruWAOavRFuO5e7gMoaISvSlTuesYd0g1aCt1K4dh3rQBphZZGtwasFf7uf0-10YqZA5p4BaMtl8dTWOSNrwWrwAmOlt4VlLPvUenjtZ2z6Mbo3b3pcrYq19PFcoYu_7KaNQ0cEyi0gj8NS-UM2zPLB8kMWmvl47C-8y6_oiwq68zAnXiIa3svJPZecs_kcGyAeofWbqgPL4KnDZMWXp6-58Hnm9nd9DacLz6W08k87GNMXNjQBhJWF02OaVbUSRGxBFc5iTBPKohZ5qdb1Rggi-Mq5ZQ2PK5wAZQnSYJpHJ8Hbx90_Ui-Dn4Wm52wHKRkCvRgNzSKChyRNPPk5X9JQgmhNM0L6tGLf9CtHozy79j4pTouT1xgT70-UUO1g3rTG7HzPdr8XCkPvDkBvqdMNoYpLuxvLqbHh0bxD2Nj40M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1550006390</pqid></control><display><type>article</type><title>Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients: Insights From the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>NICHOLLS, Stephen J ; MURAT TUZCU, E ; WOLSKI, Kathy ; BAYTURAN, Ozgur ; LAVOIE, Andrea ; UNO, Kiyoko ; KUPFER, Stuart ; PEREZ, Alfonso ; NESTO, Richard ; NISSEN, Steven E</creator><creatorcontrib>NICHOLLS, Stephen J ; MURAT TUZCU, E ; WOLSKI, Kathy ; BAYTURAN, Ozgur ; LAVOIE, Andrea ; UNO, Kiyoko ; KUPFER, Stuart ; PEREZ, Alfonso ; NESTO, Richard ; NISSEN, Steven E</creatorcontrib><description>The purpose of this study was to determine the factors associated with the favorable effect of pioglitazone on atheroma progression.
Diabetes mellitus is associated with accelerated coronary atheroma progression. Pioglitazone slowed progression compared with glimepiride in this population.
In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. Coronary atheroma progression was evaluated by serial intravascular ultrasound. The relationship between changes in biochemical parameters, percent atheroma volume, and total atheroma volume was investigated.
Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol (HDL-C) and reductions in glycated hemoglobin, triglycerides, and C-reactive protein. Significant correlations were observed between changes in percent atheroma volume and triglycerides (r = 0.15, p = 0.04), triglyceride/HDL-C ratio (r = 0.16, p = 0.03), and glycated hemoglobin (r = 0.16, p = 0.03) with pioglitazone, and changes in low-density lipoprotein cholesterol (r = -0.15, p = 0.05), apolipoprotein B (r = -0.16, p = 0.04), and apolipoprotein A-I (r = -0.20, p = 0.01) with glimepiride. Substantial atheroma regression, compared to progression, was associated with greater relative increases in HDL-C (14.2% vs. 7.8%, p = 0.04), relative decreases in triglycerides (-13.3% vs. -1.9%, p = 0.045), triglyceride/HDL-C ratio (-22.5 vs. -9.9%, p = 0.05), and decrease in glycated hemoglobin (-0.6% vs. -0.3%, p = 0.01). Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were associated with changes in percent atheroma volume (p = 0.03) and total atheroma volume (p = 0.02).
Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed atheroma progression in diabetic patients. This finding highlights the potential importance of targeting atherogenic dyslipidemia in diabetic patients with coronary artery disease.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2010.06.055</identifier><identifier>PMID: 21211686</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Atherosclerosis ; Atherosclerosis (general aspects, experimental research) ; Atherosclerosis - blood ; Atherosclerosis - complications ; Atherosclerosis - diagnostic imaging ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology ; Cardiology. Vascular system ; Cardiovascular disease ; Cholesterol ; Cholesterol, HDL - blood ; Cholesterol, HDL - drug effects ; Coronary Artery Disease - blood ; Coronary Artery Disease - complications ; Coronary Artery Disease - diagnostic imaging ; Coronary heart disease ; Coronary Stenosis - blood ; Coronary Stenosis - complications ; Coronary Stenosis - diagnostic imaging ; Diabetes ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes. Impaired glucose tolerance ; Disease Progression ; Double-Blind Method ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Follow-Up Studies ; Glucose ; Heart ; Heart attacks ; Humans ; Hypertension ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - therapeutic use ; Lipoproteins ; Medical sciences ; Normal distribution ; Prognosis ; Prospective Studies ; Thiazolidinediones - administration & dosage ; Thiazolidinediones - therapeutic use ; Triglycerides ; Triglycerides - blood ; Ultrasonic imaging ; Ultrasonography, Interventional - methods</subject><ispartof>Journal of the American College of Cardiology, 2011-01, Vol.57 (2), p.153-159</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Jan 11, 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23871202$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21211686$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NICHOLLS, Stephen J</creatorcontrib><creatorcontrib>MURAT TUZCU, E</creatorcontrib><creatorcontrib>WOLSKI, Kathy</creatorcontrib><creatorcontrib>BAYTURAN, Ozgur</creatorcontrib><creatorcontrib>LAVOIE, Andrea</creatorcontrib><creatorcontrib>UNO, Kiyoko</creatorcontrib><creatorcontrib>KUPFER, Stuart</creatorcontrib><creatorcontrib>PEREZ, Alfonso</creatorcontrib><creatorcontrib>NESTO, Richard</creatorcontrib><creatorcontrib>NISSEN, Steven E</creatorcontrib><title>Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients: Insights From the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>The purpose of this study was to determine the factors associated with the favorable effect of pioglitazone on atheroma progression.
Diabetes mellitus is associated with accelerated coronary atheroma progression. Pioglitazone slowed progression compared with glimepiride in this population.
In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. Coronary atheroma progression was evaluated by serial intravascular ultrasound. The relationship between changes in biochemical parameters, percent atheroma volume, and total atheroma volume was investigated.
Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol (HDL-C) and reductions in glycated hemoglobin, triglycerides, and C-reactive protein. Significant correlations were observed between changes in percent atheroma volume and triglycerides (r = 0.15, p = 0.04), triglyceride/HDL-C ratio (r = 0.16, p = 0.03), and glycated hemoglobin (r = 0.16, p = 0.03) with pioglitazone, and changes in low-density lipoprotein cholesterol (r = -0.15, p = 0.05), apolipoprotein B (r = -0.16, p = 0.04), and apolipoprotein A-I (r = -0.20, p = 0.01) with glimepiride. Substantial atheroma regression, compared to progression, was associated with greater relative increases in HDL-C (14.2% vs. 7.8%, p = 0.04), relative decreases in triglycerides (-13.3% vs. -1.9%, p = 0.045), triglyceride/HDL-C ratio (-22.5 vs. -9.9%, p = 0.05), and decrease in glycated hemoglobin (-0.6% vs. -0.3%, p = 0.01). Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were associated with changes in percent atheroma volume (p = 0.03) and total atheroma volume (p = 0.02).
Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed atheroma progression in diabetic patients. This finding highlights the potential importance of targeting atherogenic dyslipidemia in diabetic patients with coronary artery disease.</description><subject>Atherosclerosis</subject><subject>Atherosclerosis (general aspects, experimental research)</subject><subject>Atherosclerosis - blood</subject><subject>Atherosclerosis - complications</subject><subject>Atherosclerosis - diagnostic imaging</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular disease</subject><subject>Cholesterol</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, HDL - drug effects</subject><subject>Coronary Artery Disease - blood</subject><subject>Coronary Artery Disease - complications</subject><subject>Coronary Artery Disease - diagnostic imaging</subject><subject>Coronary heart disease</subject><subject>Coronary Stenosis - blood</subject><subject>Coronary Stenosis - complications</subject><subject>Coronary Stenosis - diagnostic imaging</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Disease Progression</subject><subject>Double-Blind Method</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Follow-Up Studies</subject><subject>Glucose</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Lipoproteins</subject><subject>Medical sciences</subject><subject>Normal distribution</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Thiazolidinediones - administration & dosage</subject><subject>Thiazolidinediones - therapeutic use</subject><subject>Triglycerides</subject><subject>Triglycerides - blood</subject><subject>Ultrasonic imaging</subject><subject>Ultrasonography, Interventional - methods</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kkuP0zAUhQMCMWXgD7BAlkaIYZGOnafDrnQ6TKSiVu0glpXj3CSuXDvYTlH59bgz5blg41g3n845vvcGwSuCxwST7Go73jLOxxH2BZyNcZo-DkYkTWkYp0X-JBjhPE5Dgov8LHhu7RZjnFFSPAvOIhIRktFs9OjTXH8DI1SLXAfozohWHrgv1HB1K9ouvAZlhTugueh1b7QDodC00xKsA6MlWjEnNCotmliruWAOavRFuO5e7gMoaISvSlTuesYd0g1aCt1K4dh3rQBphZZGtwasFf7uf0-10YqZA5p4BaMtl8dTWOSNrwWrwAmOlt4VlLPvUenjtZ2z6Mbo3b3pcrYq19PFcoYu_7KaNQ0cEyi0gj8NS-UM2zPLB8kMWmvl47C-8y6_oiwq68zAnXiIa3svJPZecs_kcGyAeofWbqgPL4KnDZMWXp6-58Hnm9nd9DacLz6W08k87GNMXNjQBhJWF02OaVbUSRGxBFc5iTBPKohZ5qdb1Rggi-Mq5ZQ2PK5wAZQnSYJpHJ8Hbx90_Ui-Dn4Wm52wHKRkCvRgNzSKChyRNPPk5X9JQgmhNM0L6tGLf9CtHozy79j4pTouT1xgT70-UUO1g3rTG7HzPdr8XCkPvDkBvqdMNoYpLuxvLqbHh0bxD2Nj40M</recordid><startdate>20110111</startdate><enddate>20110111</enddate><creator>NICHOLLS, Stephen J</creator><creator>MURAT TUZCU, E</creator><creator>WOLSKI, Kathy</creator><creator>BAYTURAN, Ozgur</creator><creator>LAVOIE, Andrea</creator><creator>UNO, Kiyoko</creator><creator>KUPFER, Stuart</creator><creator>PEREZ, Alfonso</creator><creator>NESTO, Richard</creator><creator>NISSEN, Steven E</creator><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20110111</creationdate><title>Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients: Insights From the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study</title><author>NICHOLLS, Stephen J ; MURAT TUZCU, E ; WOLSKI, Kathy ; BAYTURAN, Ozgur ; LAVOIE, Andrea ; UNO, Kiyoko ; KUPFER, Stuart ; PEREZ, Alfonso ; NESTO, Richard ; NISSEN, Steven E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p301t-f8fe4ad9f70869d492a40b7120c4be3a6016bd0ee633b5c88fc3b09e8c4440833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Atherosclerosis</topic><topic>Atherosclerosis (general aspects, experimental research)</topic><topic>Atherosclerosis - blood</topic><topic>Atherosclerosis - complications</topic><topic>Atherosclerosis - diagnostic imaging</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular disease</topic><topic>Cholesterol</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, HDL - drug effects</topic><topic>Coronary Artery Disease - blood</topic><topic>Coronary Artery Disease - complications</topic><topic>Coronary Artery Disease - diagnostic imaging</topic><topic>Coronary heart disease</topic><topic>Coronary Stenosis - blood</topic><topic>Coronary Stenosis - complications</topic><topic>Coronary Stenosis - diagnostic imaging</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Disease Progression</topic><topic>Double-Blind Method</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Follow-Up Studies</topic><topic>Glucose</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Lipoproteins</topic><topic>Medical sciences</topic><topic>Normal distribution</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Thiazolidinediones - administration & dosage</topic><topic>Thiazolidinediones - therapeutic use</topic><topic>Triglycerides</topic><topic>Triglycerides - blood</topic><topic>Ultrasonic imaging</topic><topic>Ultrasonography, Interventional - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NICHOLLS, Stephen J</creatorcontrib><creatorcontrib>MURAT TUZCU, E</creatorcontrib><creatorcontrib>WOLSKI, Kathy</creatorcontrib><creatorcontrib>BAYTURAN, Ozgur</creatorcontrib><creatorcontrib>LAVOIE, Andrea</creatorcontrib><creatorcontrib>UNO, Kiyoko</creatorcontrib><creatorcontrib>KUPFER, Stuart</creatorcontrib><creatorcontrib>PEREZ, Alfonso</creatorcontrib><creatorcontrib>NESTO, Richard</creatorcontrib><creatorcontrib>NISSEN, Steven E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NICHOLLS, Stephen J</au><au>MURAT TUZCU, E</au><au>WOLSKI, Kathy</au><au>BAYTURAN, Ozgur</au><au>LAVOIE, Andrea</au><au>UNO, Kiyoko</au><au>KUPFER, Stuart</au><au>PEREZ, Alfonso</au><au>NESTO, Richard</au><au>NISSEN, Steven E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients: Insights From the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>2011-01-11</date><risdate>2011</risdate><volume>57</volume><issue>2</issue><spage>153</spage><epage>159</epage><pages>153-159</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><abstract>The purpose of this study was to determine the factors associated with the favorable effect of pioglitazone on atheroma progression.
Diabetes mellitus is associated with accelerated coronary atheroma progression. Pioglitazone slowed progression compared with glimepiride in this population.
In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. Coronary atheroma progression was evaluated by serial intravascular ultrasound. The relationship between changes in biochemical parameters, percent atheroma volume, and total atheroma volume was investigated.
Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol (HDL-C) and reductions in glycated hemoglobin, triglycerides, and C-reactive protein. Significant correlations were observed between changes in percent atheroma volume and triglycerides (r = 0.15, p = 0.04), triglyceride/HDL-C ratio (r = 0.16, p = 0.03), and glycated hemoglobin (r = 0.16, p = 0.03) with pioglitazone, and changes in low-density lipoprotein cholesterol (r = -0.15, p = 0.05), apolipoprotein B (r = -0.16, p = 0.04), and apolipoprotein A-I (r = -0.20, p = 0.01) with glimepiride. Substantial atheroma regression, compared to progression, was associated with greater relative increases in HDL-C (14.2% vs. 7.8%, p = 0.04), relative decreases in triglycerides (-13.3% vs. -1.9%, p = 0.045), triglyceride/HDL-C ratio (-22.5 vs. -9.9%, p = 0.05), and decrease in glycated hemoglobin (-0.6% vs. -0.3%, p = 0.01). Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were associated with changes in percent atheroma volume (p = 0.03) and total atheroma volume (p = 0.02).
Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed atheroma progression in diabetic patients. This finding highlights the potential importance of targeting atherogenic dyslipidemia in diabetic patients with coronary artery disease.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>21211686</pmid><doi>10.1016/j.jacc.2010.06.055</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 2011-01, Vol.57 (2), p.153-159 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_822902156 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Atherosclerosis Atherosclerosis (general aspects, experimental research) Atherosclerosis - blood Atherosclerosis - complications Atherosclerosis - diagnostic imaging Biological and medical sciences Blood and lymphatic vessels Cardiology Cardiology. Vascular system Cardiovascular disease Cholesterol Cholesterol, HDL - blood Cholesterol, HDL - drug effects Coronary Artery Disease - blood Coronary Artery Disease - complications Coronary Artery Disease - diagnostic imaging Coronary heart disease Coronary Stenosis - blood Coronary Stenosis - complications Coronary Stenosis - diagnostic imaging Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Disease Progression Double-Blind Method Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Follow-Up Studies Glucose Heart Heart attacks Humans Hypertension Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Lipoproteins Medical sciences Normal distribution Prognosis Prospective Studies Thiazolidinediones - administration & dosage Thiazolidinediones - therapeutic use Triglycerides Triglycerides - blood Ultrasonic imaging Ultrasonography, Interventional - methods |
| title | Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients: Insights From the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T14%3A53%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lowering%20the%20Triglyceride/High-Density%20Lipoprotein%20Cholesterol%20Ratio%20Is%20Associated%20With%20the%20Beneficial%20Impact%20of%20Pioglitazone%20on%20Progression%20of%20Coronary%20Atherosclerosis%20in%20Diabetic%20Patients:%20Insights%20From%20the%20PERISCOPE%20(Pioglitazone%20Effect%20on%20Regression%20of%20Intravascular%20Sonographic%20Coronary%20Obstruction%20Prospective%20Evaluation)%20Study&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=NICHOLLS,%20Stephen%20J&rft.date=2011-01-11&rft.volume=57&rft.issue=2&rft.spage=153&rft.epage=159&rft.pages=153-159&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/j.jacc.2010.06.055&rft_dat=%3Cproquest_pubme%3E822902156%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1550006390&rft_id=info:pmid/21211686&rfr_iscdi=true |